Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Korro Bio, Inc. (KRRO : NSDQ)

• Company Description    Korro Bio Inc. is an RNA editing company focused on the discovery and development of a new class of precision genetic medicines for both rare and highly prevalent diseases. Korro Bio Inc., formerly known as Frequency Therapeutics Inc., is based in LEXINGTON, Mass. Number of Employees: 104

• Price / Volume Information    Yesterday's Closing Price: $7.96 Daily Weekly Monthly 20 Day Moving Average: 468,664 shares Shares Outstanding: 9.42 (millions) Market Capitalization: $74.96 (millions) Beta: 3.03 52 Week High: $55.89 52 Week Low: $5.20 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 29.43% 26.69% 12 Week -76.73% -77.15% Year To Date -79.09% -81.96%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 60 FIRST STREET 2ND FLOOR SUITE 250 - CAMBRIDGE,MA 02141 USA ph: 617-468-1999 fax: - ir@korrobio.com http://www.korrobio.com

• General Corporate Information    Officers Ram Aiyar - President; Chief Executive Officer and Director Oliver Dolan - Senior Vice President; Finance Ali Behbahani - Director Nessan Bermingham - Director Jean-Francois Formela - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 500946108 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/17/26 Share - Related Items Shares Outstanding: 9.42 Most Recent Split Date: 11.00 (0.02:1) Beta: 3.03 Market Capitalization: $74.96 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.86 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-9.14 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/17/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.75 Price/Cash Flow: - Price / Sales: 10.17 EPS Growth vs. Year Ago Period: 15.04% vs. Previous Quarter: 29.93% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -25.34% ROE 09/30/25 - -68.87 06/30/25 - -61.51 03/31/25 - -51.64 ROA 09/30/25 - -45.91 06/30/25 - -42.87 03/31/25 - -37.94 Current Ratio 09/30/25 - 6.71 06/30/25 - 5.98 03/31/25 - 9.41 Quick Ratio 09/30/25 - 6.71 06/30/25 - 5.98 03/31/25 - 9.41 Operating Margin 09/30/25 - -1,199.53 06/30/25 - - 03/31/25 - - Net Margin 09/30/25 - -1,199.53 06/30/25 - - 03/31/25 - - Pre-Tax Margin 09/30/25 - -1,198.11 06/30/25 - -1,452.95 03/31/25 - -1,810.56 Book Value 09/30/25 - 10.55 06/30/25 - 12.26 03/31/25 - 14.80 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - 0.00 06/30/25 - 0.00 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - 0.00 06/30/25 - 0.00 03/31/25 - 0.00

Powered by Zacks Investment Research ©